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Abstract
Background: The kynurenine pathway (KP) is the main route of tryptophan degradation in the human body and
generates several neuroactive and immunomodulatory metabolites. Altered levels of KP-metabolites have been
observed in neuropsychiatric and neurodegenerative disorders as well as in patients with affective disorders. The
purpose of the present study was to investigate if skin derived human fibroblasts are useful for studies of
expression of enzymes in the KP.
Methods: Fibroblast cultures were established from cutaneous biopsies taken from the arm of consenting
volunteers. Such cultures were subsequently treated with interferon (IFN)-g 200 U/ml and/or tumor necrosis factor
(TNF)-a, 100 U/ml for 48 hours in serum-free medium. Levels of transcripts encoding different enzymes were
determined by real-time PCR and levels of kynurenic acid (KYNA) were determined by HPLC.
Results: At base-line all cultures harbored detectable levels of transcripts encoding KP enzymes, albeit with
considerable variation across individuals. Following cytokine treatment, considerable changes in many of the
transcripts investigated were observed. For example, increases in the abundance of transcripts encoding
indoleamine 2,3-dioxygenase, kynureninase or 3-hydroxyanthranilic acid oxygenase and decreases in the levels of
transcripts encoding tryptophan 2,3-dioxygenase, kynurenine aminotransferases or quinolinic acid
phosphoribosyltransferase were observed following IFN-g and TNF-a treatment. Finally, the fibroblast cultures
released detectable levels of KYNA in the cell culture medium at base-line conditions, which were increased after
IFN-g, but not TNF-a, treatments.
Conclusions: All of the investigated genes encoding KP enzymes were expressed in human fibroblasts. Expression
of many of these appeared to be regulated in response to cytokine treatment as previously reported for other cell
types. Fibroblast cultures, thus, appear to be useful for studies of disease-related abnormalities in the kynurenine
pathway of tryptophan degradation.
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Introduction
The kynurenine pathway (KP) is the main route of tryp-
tophan degradation in the human body and generates
several neuroactive and immunomodulatory metabolites
[1,2]. KP activity has the potential to affect a range of
neurotransmitter systems in the brain including
glutamatergic, cholinergic and serotonergic transmission
[2-4]. Indeed, altered levels of KP-metabolites have been
observed in neuropsychiatric and neurodegenerative dis-
orders [5-8] as well as in patients with affective disor-
ders [9-13]. While experimental studies support an
involvement of kynurenine metabolites in the pathogen-
esis of both psychiatric and neurodegenerative disorders
[14-20], the underlying cause of the dysregulation of
kynurenine metabolism in these disorders is not known.
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KP, which thereby appear to serve both as a direct
defense mechanism and as a means of modulating the
immune response [1,21]. The enzyme indoleamine 2,3-
dioxygenase (IDO1) is the first and rate-limiting step of
this pathway and is highly induced by the pro-inflamma-
tory cytokine interferon (IFN)-g [22,23]. However, it is
not clear if pro-inflammatory cytokines affect expression
of genes encoding other enzymes of the KP. While
human fibroblasts have previously been employed for
studying the role of IDO1 in controlling experimental
infections [24-26], expression or functionality of genes
encoding downstream enzymes in the KP have not been
investigated in such cells. Since alterations in the KP
may potentially reflect the pathophysiology of several
neuropsychiatric disorders, it is of major importance to
study the KP in primary cells obtained from humans. In
the present study, we have established human ex vivo
skin fibroblast cell cultures as a successful approach to
study the KP. We investigated if transcripts encoding
enzymes in the kynurenine pathway can be detected in
these cells and if their relative abundances are modu-
lated by IFN-g and/or tumor necrosis factor (TNF)-a.
Materials and methods
Tissue isolation and culture
To establish fibroblast cultures, a cutaneous biopsy was
taken from the arm of seven consenting volunteers
recruited at Karolinska University Hospital Huddinge.
Biopsies were minced and placed in 35 mm dishes
(Corning Incorporated, Corning NY, USA) under a ster-
ile glass coverslip and cultured in DMEM Glutamax, 10
mM HEPES, 1X MEM amino acids, 1X sodium pyruvate
supplemented with 100 U/ml penicillin, 100 μg/ml
streptomycin, 15% fetal calf serum (all from Invitrogen,
Paisley, UK), in a humidified 37°C, 5% CO2 incubator.
The regional ethics committee approved the study (04-
273/1, supplements 2006/637-32 and 2009-06-12).
Cytokine treatment
After 2 passages, cells were seeded into 6-well plates
(Corning Inc.). At confluence, cytokine treatment was
performed during 48 hours using human recombinant
TNF-a 100 U/ml or IFN-g 200 U/ml (PeproTech, Lon-
don, U.K.) in serum-free media, otherwise as above.
Experiments were ended by removal and freezing of the
supernatants and addition of lysis buffer to the cell
monolayer, see below.
RNA extraction and reverse transcription
Total RNA was extracted from the cells using the
RNeasy Mini kit (Qiagen, GmbH, Hilden, Germany).
The amount and purity of the RNA was assessed by
spectrophotometry using a Nanodrop ND-1000
(NanoDrop Technologies, Wilmington, DE, USA). Total
RNA (250 ng) was subsequently treated with 1 unit of
amplification grade DNase I (Invitrogen) for 15 min at
room temperature and inactivated by the addition of 2.5
mM EDTA followed by incubation at 65°C for 10 min
according to the manufacturer’s instructions. The
DNase-treated RNA was subsequently reverse tran-
scribed in 20 μl reactions containing the following
reagents from Invitrogen; 250 ng of Oligo(dT) primer, 1
× First Strand Buffer, 10 mM DTT and 500 μMo fe a c h
dNTP and 100 U Superscript II. cDNA synthesis was
allowed to proceed for 1 h at 42°C before inactivation at
72°C for 10 min.
Real-time PCR and data analysis
One μl cDNA templates were added to triplicate 25 μl
reaction mixtures using Platinum SYBR Green qPCR
Supermix UDG (Invitrogen). An ABI Prism 7500 real-
time thermocycler was used (Applied Biosystems, Palo
Alto, CA, USA). Primers (Invitrogen) are provided in
Table 1. Threshold cycle (Ct) values from the exponen-
tial phase of the PCR amplification plot for each target
transcript were normalized to that encoding glyceralde-
hyd-3-phosphate dehydrogenase (GAPDH). From these
values, fold-differences in the levels of transcripts
Table 1 Transcripts analyzed by real-time PCR, gene
symbols and primer sequences
Target
transcript
Gene Polarity Sequence (5’®3’)
IDO1 INDO Sense GCATTTTTCAGTGTTCTTCGCATA
Anti-sense CATACACCAGACCGTCTGATAGCT
TDO TDO2 Sense GAACATCTTTTTATCATAACTCATCAAGCT
Anti-sense ACAACCTTAAGCATGTTCCTTTCAT
KMO KMO Sense TGTAATCCTCCAAGCTTCAATCTG
Anti-sense CTAGTAGATGCCCACTGAATATTTGTG
HAAO HAAO Sense GGACGTTCTGTTTGAGAAGTGGTT
Anti-sense AGCTGAAGAACTCCTGGATGATG
KAT1 CCBL1 Sense CCTGCTAAGGCTCAGGTATAACCT
Anti-sense GGACTCAAGCCTAAAGGCAACTC
KAT2 AADAT Sense CACATCTGGCAGCCAACAAG
Anti-sense CACTGGCAACATTAATAATGTTGCA
KAT3 CCBL2 Sense ACTATCAGCCATCCCCGTTTC
Anti-sense AATGAAGCAAAAACGCACAAACT
KAT4 GOT2 Sense TGTGGTGTGCAGCCTCTCAT
Anti-sense AAGCCTGAACCCAGCTAGCA
KYNU KYNU Sense ACAGGATCTGCCTCCAGTTGA
Anti-sense TGGCCCACTTATCTAGTTCTTCTTC
QPRT QPRT Sense ACACCGGCCATGGGTTAAC
Anti-sense GCCCCATTGGCCACTGA
GAPDH GAPDH Sense CACATGGCCTCCAAGGAGTAA
Anti-sense TGAGGGTCTCTCTCTTCCTCTTGT
Asp et al. Journal of Inflammation 2011, 8:25
http://www.journal-inflammation.com/content/8/1/25
Page 2 of 7between individual untreated and treated cell cultures
were calculated according to the formula 2
-ΔΔCt [27].
Analysis of kynurenic acid levels
Cell culture supernatants (1.0 ml) were collected and
kept in -20°C until analysis. In order to precipitate resi-
dual protein, samples were centrifuged at 20800 g for 5
minutes and an equal volume of 0.4 M perchloric acid
was added to the supernatants. After a second centrifu-
gation 70% perchloric acid (300 μl) was added, and
thereafter the supernatants were centrifuged twice at
20800 g for 5 minutes.
Analysis of KYNA was performed using an isocratic
reversed-phase high-performance liquid chromatography
(HPLC) system, including a dual-piston, high-liquid
delivery pump (Bischoff Chromatography, Leonberg,
Germany), a ReproSil-Pur C18 column (150 × 4 mm,
Dr. Maisch GmbH, Ammerbuch, Germany) and a fluor-
escence detector (FP 2020, Jasco Ltd., Hachioji City,
Japan) with an excitation wavelength of 344 nm and an
emission wavelength of 398 nm (18 nm bandwidth). A
mobile phase of 50 mM sodium acetate (pH 6.2,
adjusted with acetic acid) and 7.0% acetonitrile was
pumped through the reversed-phase column at a flow
rate of 0.5 mL/min. Samples of 50 μL were manually
injected into a Rheodyne injector with a sample loop of
50 μl( R h e o d y n e ,R h o n e r tP a r k ,C A ,U S A ) .Z i n ca c e t a t e
(0.5 M not pH adjusted) was delivered postcolumn by a
peristaltic pump (P-500; Pharmacia, Uppsala, Sweden) at
a flow rate of 0.10 ml/hr. Signals from the fluorescence
detector were transferred to a computer for analysis
with Datalys Azur software (Datalys, Grenoble, France).
The retention time of KYNA was about 7-8 minutes.
Initially, the sensitivity of the system was verified by
analysis of a standard mixture of KYNA with concentra-
tions from 1 to 30 nM, which resulted in a linear stan-
dard plot.
Statistics
Comparisons across treatments were done by repeated
measures ANOVA with Bonferroni’s Multiple Compari-
son Test using GraphPad (GraphPad Software, Inc., San
Diego, CA, USA).
Results
Detection of transcripts encoding KP enzymes
All the investigated kynurenine pathway transcripts
(IDO1, TDO, KAT1, KAT2, KAT3, KAT4, KMO,
KYNU, HAAO, QPRT) were detected in untreated
fibroblast cell cultures, Figure 1. The levels of expression
varied considerably across the different genes, with tran-
scripts encoding IDO1 detected at the lowest level and
those encoding KAT3 detected at the highest level (dif-
ference 8 × 10
3 fold). The variation across individual
cultures (n = 7), ranged from 2.5 (KAT3) to 145-fold
(KYNU).
Modulation of transcript-levels by IFN-g and/or TNF-a
The potential effects of IFN-g, TNF-a, or a combination
of IFN-g and TNF-a on kynurenine pathway transcripts
were investigated in the fibroblast cell cultures, see Fig-
ure 2. The levels of transcripts encoding IDO1 were sig-
nificantly increased (> 10
5-fold) in cultures treated with
IFN-g ( p<0 . 0 0 1 )a sw e l la sI F N - g together with TNF-a
(p < 0.001) compared to untreated cultures although no
effect of TNF-a alone was observed (Figure 2A). Tran-
scripts encoding tryptophan 2,3-dioxygenase (TDO), on
the other hand, were significantly down-regulated in
cultures treated with a combination of IFN-g and TNF-
a (20-fold; p < 0.001) as compared to untreated cells or
cells treated with the individuals cytokines (Figure 2B).
Moreover, levels of transcripts encoding the kynurenine
aminotransferases (KATs) were either unaffected or
down-regulated by the cytokine treatments. Whereas
KAT2 was unaffected by cytokine treatment, KAT1 and
KAT3 transcript levels were reduced following treat-
ment with the combination of IFN-g and TNF-a (2.6-
fold, p < 0.001 and 1.7-fold, p < 0.01 respectively, Figure
2C, D and 2E). Levels of transcripts encoding mitochon-
drial aspartate aminotransferase (mitAAT, i.e KAT4)
were significantly down regulated (1.5-fold) in cultures
treated with IFN-g (p < 0.05) and further decreased with
the combination of IFN-g and TNF-a (2.7-fold; p <
0.001, Figure 2F). Levels of transcripts encoding kynure-
nine 3-monooxygenase (KMO) observed in the
Figure 1 Relative levels of transcripts encoding enzymes in the
kynurenine pathway in human skin-derived fibroblasts from 7
individuals. Transcripts encoding the following enzymes were
investigated; Indoleamine 2,3-dioxygenase 1 (IDO1), Tryptophan 2,3-
dioxygenase (TDO), Kynurenine aminotransferases (KAT) 1-4,
Kynurenine 3-monooxygenase (KMO), Kynureninase (KYNU), 3-
Hydroxyanthranilic acid oxygenase (HAAO) and Quinolinic acid
phosphoribosyltransferase (QPRT).
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cytokine treatment (Figure 2G). Levels of transcripts
encoding kynureninase (KYNU) were up-regulated fol-
lowing IFN-g treatment (8-fold; p < 0.01) or with TNF-
a treatment (28-fold; p < 0.001). A further increase in
the levels of KYNU transcripts was observed with the
combination of IFN-g and TNF-a (650-fold; p < 0.001,
Figure 2H). Levels of transcripts encoding 3-
Figure 2 Relative levels of transcripts encoding enzymes in the kynurenine pathway (A-J) following treatment with IFN-g (200 U/ml),
TNF-a (100 U/ml) or the combination of these two cytokines (IFN-g+TNF-a) during 48 hrs in serum-free cell culture medium (n = 7).
Levels of all transcripts are normalized to levels observed in untreated control cells (base-line). *p < 0.05, **p < 0.01, ***p < 0.001.
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regulated only in cultures treated with the combination
of IFN-g and TNF-a (12-fold, p < 0.001, Figure 2I).
Levels of transcripts encoding quinolinate phosphoribo-
syltransferase (QPRT) were down-regulated by the com-
bination of IFN-g and TNF-a (5-fold, p < 0.001), but
unaffected by the individual cytokines (Figure 2J).
Effects on KYNA levels
To address potential functionality of the KP in these
human fibroblast cultures, we measured the accumula-
tion of KYNA, one of the end metabolites in the KP in
the supernatants. Levels of KYNA were detectable in
supernatants from untreated ex vivo fibroblast cultures
(3.4 ± 0.6 nmol/l). Significantly (p < 0.0001) higher
levels were detected in supernatants of cells treated with
IFN-g (27.2 ± 18 nmol/l) or with IFN-g and TNF-a
(39.8 ± 20.1 nmol/l) as compared to supernatants from
untreated cells. TNF-a alone did not cause a significant
increase in the accumulation of KYNA.
Discussion
We here report, for the first time, that human skin
fibroblast cultures express detectable levels of transcripts
encoding the different enzymes of the KP. Substantial
differences in the basal levels of expression across genes
and individuals were observed which are likely to be
explained by genetic and epigenetic variation between
individual cultures. Following treatment with IFN-g,
these cultures exhibited relative increases of > 10
5-fold
for transcripts encoding IDO1. We also found that
human skin fibroblast cultures can release KYNA, and
that this release was significantly increased following
IFN-g, but not TNF-a, treatment, indicating that at least
some of the transcriptional changes observed in
response to IFN-g are functional in these cells.
Thus, in agreement with previous reports [28,29],
human fibroblast cultures appear to be able to increase
the rate of tryptophan degradation along the kynurenine
pathway in response to IFN-g treatment. Our present
findings support the notion that IDO1 is the major
determinant of this response in human fibroblasts, as is
a l s ot h ec a s ei nm a n yo t h e rc e l lt y p e s ,d e r i v e db o t h
from the brain and from peripheral tissues [30]. For
example, Guillemin and co-workers reported increased
levels of KYNA and increased levels of transcripts
encoding IDO1 following IFN-g, but not following TNF-
a treatment of human fetal astrocytes [23]. More
recently, increased levels of KYNA and transcripts
encoding IDO1 were also observed in primary neurons
and neuroblastoma cells following IFN-g treatment [22].
While Heyes and colleagues [31] reported a small
increase in KMO activity in monocytes following IFN-g
treatment, we did not observe any significant effect on
transcripts encoding KMO following cytokine treatment.
Our observations are thus in agreement with the effects
of IFN-g observed in neuronal cells [22]. Whereas IFN-g
or TNF-a, alone or in combination, markedly increased
transcripts of KYNU and HAAO, we observed no effect
or even decreased levels of transcripts encoding KAT
enzymes by these cytokines. Indeed there is no consen-
sus in earlier studies regarding the response of the KAT
enzymes to IFN-g treatment. Whereas increases in the
levels of KAT 1 and KAT 2 were observed in fetal astro-
cytes following IFN-g treatment [23], no effect on the
levels of transcripts encoding these enzymes was
observed in neuronal cells [22]. In neuroblastoma cells,
levels of transcripts encoding TDO were reduced by the
IFN-g treatment whereas no effects on the levels of tran-
scripts encoding KAT1, KAT2, KYNU, KMO, HAAO or
QPRT were observed [22]. Differences in transcription
of genes encoding enzymes involved in the KP in
response to IFN-g therefore most likely exist across cell
types. These differences probably also explain some of
the differences observed across cell types in their
enzyme activities and in their abilities to form kynure-
nine and quinolinic acid [31]. The physiological role of
the kynurenine pathway in skin-derived fibroblasts is
not known but may involve effects not primarily related
to acetylcholine or glutamate receptors such as effects
on cell proliferation [1], cytokine release [32] or micro-
bial growth [21,24-26,33] as described in other periph-
eral cell types.
The increases in KYNU and HAAO, and decrease in
levels of transcripts encoding QPRT, following IFN-g
and TNF-a treatment suggest that such treatment can
potentially alter the accumulation of other metabolites
generated by the KP, such as quinolinic acid. It should
also be noted that TNF-a treatment alone caused a pro-
nounced and selective increase (almost 30-fold) in levels
of transcripts encoding KYNU, suggesting a direct influ-
ence of TNF-a on expression of this gene. Thus, it
appears as if certain cytokines can differentially affect
expression of genes in the KP, at least in fibroblasts (for
overview see Figure 3), and thereby potentially modulate
levels of individual metabolites.
Fibroblast cultures derived from patients and healthy
controls have previously been used to study a range of
CNS-diseases. For example, in fibroblasts from patients
with schizophrenia, alterations in pathways involved in
cell cycle regulation and RNA processing have been
identified [34]. Moreover, alterations in growth, mor-
phology, cell adhesion, apoptotic pathways, composition
of phospholipid fatty acids in the plasma membrane and
glutathione synthesis are reported [35-39]. Aberrant
amino acid transport has been identified in fibroblast
from patients with schizophrenia, bipolar disorder as
well as autism [40-42]. These reports suggest that
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the molecular level in patients with psychiatric disorders
and thus provide a useful method to investigate
mechanisms underlying such disorders. The advantage
of studying ex vivo cultures compared to postmortem
tissue or blood samples is that in such cultures con-
founding factors like medical treatments are minimized.
Furthermore, in contrast to using clinical samples, ex
vivo cell cultures can also be used to conduct well-con-
trolled studies of potential gene-environment interac-
tions. The present findings suggest that fibroblast
cultures can be used to study disease-related abnormal-
ities in the kynurenine pathway of tryptophan
degradation.
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